Literature DB >> 8374952

Reduction of p53 gene dosage does not increase initiation or promotion but enhances malignant progression of chemically induced skin tumors.

C J Kemp1, L A Donehower, A Bradley, A Balmain.   

Abstract

The availability of p53 knockout mice generated by gene targeting has enabled us to investigate the functional role of the p53 tumor suppressor gene in initiation, promotion, and progression of carcinogenesis in vivo, using mouse skin as a model system. The number, size, and growth rate of benign papillomas were not increased in the p53 heterozygous mice in comparison with wild type. The p53 null mice showed a reduced yield of papillomas, but these underwent much more rapid malignant progression, with some poorly differentiated carcinomas developing after only 10 weeks of promotion. Progression rate was also greater in heterozygous than in wild-type mice and was associated with loss of the remaining wild-type allele. Most tumors from all groups had activating mutations in the H-ras gene. Absence of p53, therefore, does not augment the frequency of initiation or the rate of promotion but greatly enhances malignant progression.

Entities:  

Mesh:

Substances:

Year:  1993        PMID: 8374952     DOI: 10.1016/0092-8674(93)90461-x

Source DB:  PubMed          Journal:  Cell        ISSN: 0092-8674            Impact factor:   41.582


  118 in total

1.  Enhancement of chemical hepatocarcinogenesis by the HIV-1 tat gene.

Authors:  G Altavilla; A Caputo; M Lanfredi; C Piola; G Barbanti-Brodano; A Corallini
Journal:  Am J Pathol       Date:  2000-10       Impact factor: 4.307

2.  Transgenic mouse model for studying the transcriptional activity of the p53 protein: age- and tissue-dependent changes in radiation-induced activation during embryogenesis.

Authors:  E Gottlieb; R Haffner; A King; G Asher; P Gruss; P Lonai; M Oren
Journal:  EMBO J       Date:  1997-03-17       Impact factor: 11.598

3.  Differentiation-induced skin cancer suppression by FOS, p53, and TACE/ADAM17.

Authors:  Juan Guinea-Viniegra; Rainer Zenz; Harald Scheuch; María Jiménez; Latifa Bakiri; Peter Petzelbauer; Erwin F Wagner
Journal:  J Clin Invest       Date:  2012-07-09       Impact factor: 14.808

Review 4.  Keratinocyte apoptosis in epidermal development and disease.

Authors:  Deepak Raj; Douglas E Brash; Douglas Grossman
Journal:  J Invest Dermatol       Date:  2006-02       Impact factor: 8.551

Review 5.  Cellular mechanisms of somatic stem cell aging.

Authors:  Yunjoon Jung; Andrew S Brack
Journal:  Curr Top Dev Biol       Date:  2014       Impact factor: 4.897

6.  G1 checkpoint failure and increased tumor susceptibility in mice lacking the novel p53 target Ptprv.

Authors:  Gilles Doumont; Alain Martoriati; Chantal Beekman; Sven Bogaerts; Patrick J Mee; Fabrice Bureau; Emanuela Colombo; Myriam Alcalay; Eric Bellefroid; Francesco Marchesi; Eugenio Scanziani; Pier Giuseppe Pelicci; Jean-Christophe Marine
Journal:  EMBO J       Date:  2005-08-18       Impact factor: 11.598

Review 7.  20 years studying p53 functions in genetically engineered mice.

Authors:  Lawrence A Donehower; Guillermina Lozano
Journal:  Nat Rev Cancer       Date:  2009-09-24       Impact factor: 60.716

8.  Increased incidence of squamous cell carcinomas in Mastomys natalensis papillomavirus E6 transgenic mice during two-stage skin carcinogenesis.

Authors:  Iris Helfrich; Min Chen; Rainer Schmidt; Gerhard Fürstenberger; Annette Kopp-Schneider; David Trick; Hermann-Josef Gröne; Harald Zur Hausen; Frank Rösl
Journal:  J Virol       Date:  2004-05       Impact factor: 5.103

9.  Moloney murine leukemia virus-induced lymphomas in p53-deficient mice: overlapping pathways in tumor development?

Authors:  E W Baxter; K Blyth; L A Donehower; E R Cameron; D E Onions; J C Neil
Journal:  J Virol       Date:  1996-04       Impact factor: 5.103

10.  DNA damage-induced sustained p53 activation contributes to inflammation-associated hepatocarcinogenesis in rats.

Authors:  H-X Yan; H-P Wu; H-L Zhang; C Ashton; C Tong; J Wu; Q-J Qian; H-Y Wang; Q-L Ying
Journal:  Oncogene       Date:  2012-10-15       Impact factor: 9.867

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.